Promising use of metformin in treating neurological disorders: biomarker-guided therapies
Open Access
- 22 September 2023
- journal article
- review article
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (5) , 1045-1055
Abstract
Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, Huntington’s disease), cerebrovascular conditions (stroke), and neurodevelopmental disorders (autism spectrum disorder). Although they affect millions of individuals around the world, only a limited number of effective treatment options are available today. Since most neurological disorders express mitochondria-related metabolic perturbations, metformin, a biguanide type II antidiabetic drug, has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism. However, controversial research emerges regarding the beneficial/detrimental effects of metformin on these neurological disorders. Given that most neurological disorders have complex etiology in their pathophysiology and are influenced by various risk factors such as aging, lifestyle, genetics, and environment, it is important to identify perturbed molecular functions that can be targeted by metformin in these neurological disorders. These molecules can then be used as biomarkers to stratify subpopulations of patients who show distinct molecular/pathological properties and can respond to metformin treatment, ultimately developing targeted therapy. In this review, we will discuss mitochondria-related metabolic perturbations and impaired molecular pathways in these neurological disorders and how these can be used as biomarkers to guide metformin-responsive treatment for the targeted therapy to treat neurological disorders.Keywords
This publication has 233 references indexed in Scilit:
- Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine MetabolismCell, 2013
- Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant micePharmacology Biochemistry and Behavior, 2012
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2012
- Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signalingProceedings of the National Academy of Sciences, 2010
- Effects of Metformin in Experimental StrokeStroke, 2010
- OCT1 Expression in Adipocytes Could Contribute to Increased Metformin Action in Obese SubjectsDiabetes, 2010
- Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's DiseaseThe Journal of Neuroscience, 2009
- Antidiabetic drug metformin (Glucophage R ) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcriptionProceedings of the National Academy of Sciences, 2009
- Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stressProceedings of the National Academy of Sciences, 2008